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Background. Right ventricular pacing (RVP) has been associated with adverse outcomes, including heart failure and death.
Minimizing RVP has been proposed as a therapeutic goal for a variety of pacing devices and indications. Objective. Quantify
survival according to frequency of RVP in veterans with pacemakers. Methods. We analyzed electrograms from transtelephonic
monitoringofveteransimplantedwithpacemakersbetween1995and2005followedbytheEasternPacemakerSurveillanceCenter.
We compared all cause mortality and time to death between patients with less than 20% and more than 80% RVP. Results. Analysis
waslimitedtothe7198patientswithatleastsixtrans-telephonicmonitoringrecords(mean =21).Averagefollow-upwas5.3years.
Averageageatpacemakerimplantwassigniﬁcantlyloweramongveteranswith<20%RVP(67yearsversus72years;P<. 0001).An
equal proportion of deaths during follow-up were noted for each group: 126/565 patients (22%) with <20% RVP and 1113/4968
patients (22%) with >80% RVP. However, average post-implant survival was 4.3 years with <20% RVP versus 4.7 years with >80%
RVP (P<. 0001). Conclusions. Greater frequency (>80%) of RVP was not associated with higher mortality in this population of
veterans. Those veterans utilizing <20% RVP had a shortened adjusted survival rate (P = .0016).
1.Introduction
Right ventricular apical pacing (RVP) is commonly em-
ployed, but concerns have been raised suggesting that it
is associated with worsened mortality in the setting of
cardiomyopathy. Several trials have found an association
between more frequent RVP and adverse eﬀects, such as
atrial ﬁbrillation and congestive heart failure [1–4]. Dual-
chamber pacing can improve quality of life in the absence
of atrioventricular block, which requires less frequent RVP;
however it does not reduce the rate of stroke or death [5–
7]. As interest has grown in using biventricular pacing to
reduce mortality and symptoms in certain patients with left
ventricular systolic dysfunction, the advisability of frequent
RVP has been questioned [8]. Minimizing right ventricular
pacing has even been proposed for unselected pacemaker
patients, regardless of left ventricular function [9]. Although
multiple studies have addressed mortality, either they have
included limited numbers of subjects or had relatively short
followup intervals [1, 5, 6]. The present study from a large
national cohort of veterans retrospectively evaluates whether
the frequency of right ventricular pacing was associated with
shortenedsurvivaloralteredall-causemortalityduringlong-
term followup.
2. Methods
The Eastern Pacemaker Surveillance Center is one of two
national Veterans Administration centers established for
remote telephonic monitoring. It has served Veterans for 25
years, maintaining a large registry of transtelephonic mon-
itoring records (TTMs) and outcomes. Quality assurance2 Cardiology Research and Practice
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Figure 1: Number of TTMs versus Percentage RVP from interro-
gation. Correlation coeﬃcient is for entire group. Values analyzed
were either <20% or >80%, which fell closer to the line of identity.
(RVP = right ventricular pacing. TTMs = transtelephonic monitor
reports.)
Table 1: TTM validation for % right ventricular pacing.
Number of TTM values Number of patients Correlation
≥3 174 R = 0.825
≥6 143 R = 0.867
≥9 124 R = 0.870
≥12 112 R = 0.866
TTMs: transtelephonic monitor reports.
analysis of deidentiﬁed data from this population was used
to assess for eﬀects of frequent RVP, and potential need
for reprogramming pacemakers to minimize RVP. From this
registry of over 66,000 patients, we identiﬁed those with
permanent pacemakers which had active right ventricular
leads implanted between January 1, 1995, and December
31, 2005. This group was then limited to those with a
minimum number of TTM followups, who had either a
very high (>80%) or very low (<20%) frequency of RVP.
Frequency was determined by the TTM recordings (typically
Lead I) which lasted 30 seconds before and 15 seconds
during magnet application. The percent of paced ventricular
complex esoneachTTMwasnoted.Thevalueswereaveraged
for each patient and used as a representation of that patient’s
frequency of RVP.
We reviewed records of 174 patients from the Washing-
ton Veterans Aﬀairs Medical Center with 3 or more TTMs
to determine the minimum number of prior TTMs needed.
The average frequency of TTM-derived RVP was compared
to at least 2 independent records of frequency of RVP
obtained from implanted pacemaker generated data logs
from oﬃce-based pacemaker interrogation. A minimum of
6 TTM-derived RVP values (Table 1 and Figure 1) correlated
suﬃciently with the data log estimates (R = 0.867) so that
the current analysis required veterans with at least 6TTMs.
Our group had previously analyzed outcomes for very
high and very low frequency RVP based on those with less
than 20% right ventricular pacing (<20% RVP) and those
with greater than 80% (>80% RVP) [10] excluding patients
with atrial single chamber, biventricular pacemakers, and
implanted pacemaker deﬁbrillators. These allocations were
considered reasonable and they were used in this study.
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Figure2:Bargraphshowingpatientdistributionbypercentpacing.
Allocationofpatientstopercent-paceddecilebaseduponfrequency
of RV pacing detected by transtelephonic monitoring records.
Patients in the ﬁrst and second deciles, shown below vertical line
at 20%, were compared to patients in the ninth and tenth deciles,
shown above vertical line at 80%.
Testing for other allocations was not performed. Survival
wasassessedfromtheEasternPacemakerSurveillanceCenter
records, and veriﬁed through Veterans Aﬀairs related data
sources for all subjects in October 2006.
3.StatisticalAnalysis
The primary endpoints were all-cause mortality and post
pacemaker implant survival, measured as the time from
pacemaker insertion to death. We examined univariate
relationships between predictors (patient and pacemaker
characteristics) and outcomes using Kaplan-Meier analysis
(Proc Lifetest in SAS version 9.1). Multivariate relationships
were examined using Cox regression (Proc Phreg in SAS
version 9.1).
4. Results
We identiﬁed 7198 patients from the Eastern Pacemaker
Surveillance Center registry with six or more TTMs (Mean =
21TTMs) during the 11-year time period with either <20%
RVP (n = 565) or >80% RVP (n = 4968). This represented
77% of all patients with at least 6TTMs (Figure 2). Signiﬁ-
cant diﬀerences in the types of pacemakers and indications
for pacing were noted between the two groups (Table 2).
The average duration of post-implant followup was 5.1 ±
2.5 years in those with <20% RVP and 5.3 ± 2.4 years from
time of pacemaker implantation in those with >80% RVP
(P = .062).
Correlation of clinical variables with mortality outcomes
was analyzed in a regional group of 174 patients at the Wash-
ington Veterans Aﬀairs Medical Center (Table 3). This group
showed minor diﬀerences from the larger cohort in terms of
age, distribution between <20% RVP and >80% RVP, and
rate responsiveness. Clinical variables evaluated included the
presence of coronary artery disease, diabetes, dyslipidemia,Cardiology Research and Practice 3
Table 2: Study ﬁndings.
<20% RVP >80% RVP
Number of patients 565 4968 P = .0016
Age at implant (years) 66.67 72.10 P<. 0001
Male 552 (98%) 4889 (98%) P = ns
Rate responsiveness 516 (91%) 4732 (95%) P = .01
Pacemaker type:
Single chamber 182 (32%) 887 (18%) P = .0003
Dual chamber 383 (68%) 4081 (82%)
Indication:
Sinus node dysfunction 373 (66%) 2782 (56%) P<. 01
Atrioventricular block 192 (34%) 2186 (44%)
Average followup (years) ± SE 5.1 ± 2.5 5.3 ± 2.4 P = .062
Deaths 126 (22.3%) 1113 (22.4%) P = .39
Average time to death (years) (95% conﬁdence interval) 4.34 (3.98–4.70) 4.72 (4.60–4.84) P<. 0001
RVP = right ventricular pacing.
heart failure, hypertension, and medications (angiotensin-
converting enzyme inhibitors, angiotensin receptor blockers,
aspirin, beta-blockers, calcium channel blockers, diuretics,
and statins). There were no signiﬁcant diﬀerences in these
clinical variables in this subgroup, between patients with
<20% RVP and >80% RVP. However we cannot with a high
conﬁdencelevel conclude that other clinical variables did not
impact outcomes in the larger cohort.
Average age at time of pacemaker implant was signiﬁ-
cantly lower in the group who had <20% RVP versus >80%
RVP (67 versus 72 years; P<. 0001). The overwhelming
majority of patients were men (98% in both groups). Single-
chamber pacemakers were present in 32% of patients who
had <20% RVP and in 18% of patients who had >80% RVP
(Chi-square = 80.00, P<. 001). Sinus node dysfunction was
the pacing indication slightly more often in those patients
with <20% RVP (66%), compared to those patients with
>80% RVP (56%); whereas atrioventricular node block was
the pacing indication slightly less often in those patients with
<20% RVP (34%) compared to those patients with >80%
RVP (44%).
Kaplan-Meier analysis (Table 4 and Figure 3) found that
the patients with <20% RVP compared to patients with
>80% RVP did not diﬀer in percent of patients who survived
(22.3% versus 22.4%; Chi-square = 0.75; P = .39) or in
survival time (75% survival occurred at 6.1years (95% CI =
5.3–6.7 years) for the 20% RVP group; and at 6.4 years, (95%
CI = 6.2–6.7 years) in the >80% RVP group). Survival was
alsoassessedattwoseparatetimepointspostimplant:4years
and 9.5 years post implant. Signiﬁcantly more patients with
>80%R VPwer eali v eat4y ears;ho wev er ,at9.5y earssurvi val
rates were not signiﬁcantly diﬀerent (Figure 4).
Pacemaker type (single versus dual), age at implant,
and rate responsiveness all had signiﬁcant univariate rela-
tionships with survival time (all P<. 001). There were a
small percentage of patients in both groups without rate
responsiveness. Rate responsiveness was an independent
p r e d i c t o ro fb e t t e rs u r v i v a l( P = .01). Since the <20%
RVP versus >80% RVP patients diﬀered in age at implant,
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Figure 3: Survival function for <20% versus >80% RVP. Although
Kaplan-Meier analysis did not ﬁnd a signiﬁcant diﬀerence between
these groups when they were examined without covariates, Cox
regression analysis controlling for age at implant, pacemaker type,
and rate responsiveness showed that overall survival was better for
those veterans with >80% RVP (P = .0016). Lower age, dual-
chamber pacemaker, and rate responsiveness were associated with
better survival. Most of the diﬀerence in risk occurs between years 3
and 8 post implant. There is little diﬀerence prior to year 2.
pacemaker type, and percent with rate responsiveness, it was
necessary to do a multivariate analysis using Cox regression
in order to determine the independent eﬀect of <20% RVP
versus >80% RVP after accounting for age, pacemaker type,
and rate responsiveness. This analysis found that <20%
RVP versus >80% RVP, age at implant, and pacemaker type
together were signiﬁcantly related to survival time (Chi-
square = 333.40; P<. 0001), and that each of these variables
independently had a signiﬁcant impact on survival time
(Table 5). In multivariate analysis, patients with >80% RVP
lived signiﬁcantly longer than patients with <20% RVP (Chi-
square = 9.92; P = .0016).4 Cardiology Research and Practice
Table 3: Clinical characteristics in Washington, DC VAMC subgroup.
<20% RVP >80% RVP
Number of patients 26 148
Age at implant 73.1 74.5
Rate responsiveness 23 (88%) 146 (99%) P = .0244
Pacemaker type:
Single chamber 10 (38%) 22 (15%) P = .0105
Dual chamber 16 (62%) 126 (85%)
Coronary artery disease 9 (34.6%) 71 (48.0%) P = .2862
Diabetes mellitus 8 (30.8%) 48 (32.4%) P = 1.0000
Dyslipidemia 15 (57.7%) 76 (51.4) P = .6713
Heart failure 4 (15.4%) 33 (22.3%) P = .6042
Hypertension 19 (73.1%) 113 (76.4%) P = .8041
ACE/ARB 14 (53.8%) 87 (58.8%) P = .6707
Aspirin 13 (50%) 73 (49.3%) P = 1.0000
Beta-blocker 12 (46.2%) 62 (41.9%) P = .8301
Calcium channel blocker 4 (15.4%) 26 (17.6%) P = 1.0000
Diuretic 13 (50%) 72 (48.6%) P = 1.0000
Statin 15 (57.7%) 65 (43.9%) P = .2078
ACE/ARB = Angiotensin-converting enzyme inhibitor and/or Angiotensin receptor blocker.
RVP = right ventricular pacing.
Table 4: Kaplan-Meier results for <20% versus >80% right ventricular pacing.
Pacing Total nn Died Censored % Died 25th %-ile 95% CI 95% CI
for survival (years) lower bound upper bound
<20% 565 126 439 22.3 6.12 5.25 6.72
>80% 4972 1113 3859 22.4 6.39 6.17 6.66
Total 5537 1239 4298 22.4
Having <2 0 %R V Pi nc o m p a r i s o nt o>80% RVP was
associated with a 36% higher likelihood of death during the
followup period (P = .0016), after accounting for the eﬀects
of all other covariates. Having a single-chamber pacemaker
(versus dual chamber) was associated with a 28.6% higher
likelihood of death during the followup period (P<. 001).
Absence of rate responsiveness raised the risk of death by
29.6% (P = .01). Each year of age was associated with a
6.0% higher likelihood of death during the 5.3-year average
followup period (P<. 0001).
In order to more closely examine the concurrent eﬀects
of both percent pacing (<20% RVP versus >80% RVP) and
pacemaker type (single chamber versus dual chamber), we
coded the four possible combinations of these 2 variables:
(1) <20%: single, (2) <20%: dual, (3) >80%: single, and
(4) >80%: dual; then we completed both Kaplan-Meier
and Cox regression analyses. In the Kaplan-Meier analysis,
the group variable of percent pacing and pacemaker type
(with 4 levels) had a signiﬁcant impact on survival (Chi-
square = 41.36; P<. 0001). Patients with <20% RVP and
single-chamber pacemakers had both the highest percentage
of patients who died (30.8%) and the shortest time to
death (25% died by 4.5 years post implant). Patients with
>80% RVP and single-chamber pacemakers also had a high
percentage who died (30.5%), and a moderate survival time
(25% died by 5.5 years). The two groups with dual-chamber
pacemakers lived longer (25% died by 6.7 years for both
<20% RVP and >80% RVP) and fewer died (18.1% and
20.8% for <20% RVP and >80% RVP, resp.; Table 6). In the
Cox regression analysis with age and rate responsiveness as
covariates, the percent pacing and pacemaker type variable
(4 levels) together with age at implant and rate responsivity
were strongly related to survival (Chi-square = 332.29; P<
.0001). The age at implant, rate responsiveness, and the
combined variable (percent pacing and pacemaker type)
made signiﬁcant contributions to the regression equation
(Table 7).
Examination of the survival curves (Figure 5) shows that
duringthepost-implantfollowupperiod,patientswithdual-
chamber pacemakers were least likely to die, regardless of
whether they had <20% RVP or >80% RVP.
5. Discussion
Our study examined the relationship between the amount
of time the right ventricle is paced and subsequent mor-
tality. We evaluated patients with an indication for anti-
bradycardia pacing due to either sinus node dysfunction or
AV block. Because there are inherent diﬃculties in control-
ling percent of right ventricular pacing, this retrospectiveCardiology Research and Practice 5
Table 5: Cox regression analysis using <20% versus >80% right ventricular pacing, single versus dual pacemaker type, simple versus rate
responsive, and age as separate variables.
Variable DF Parameter estimate SE Chi-square P Hazard ratio
<20% (versus >80%) 1 0.309 0.098 9.92 .0016 1.362
Single (versus dual) 1 0.252 0.069 13.26 .0003 1.286
Simple (versus rate responsive) 1 0.259 0.101 6.58 .01 1.296
Age 1 0.059 0.004 248.63 <.0001 1.060
Table 6: Kaplan-Meier results for 4 groups.
Pacing Total nn Died Censored % Died 25th %-ile 95% CI 95% CI
for survival (years) lower bound upper bound
<20% + single 182 56 126 30.77 4.46 3.81 6.00
<20% + dual 376 68 308 18.09 6.66 6.03 7.69
>80% + single 839 256 583 30.51 5.51 5.15 6.06
>80% + dual 4080 847 3233 20.76 6.70 6.38 7.02
Total 5477 1227 4250 22.40
RVP = right ventricular pacing.
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Figure 4: Survival outcomes at 4 years and 9.5 years post implant.
At 4 years post implant, 90% of patients with >80% RVP (95%
CI , 89%–91%) remain alive, compared with 86% of patients with
<20% RVP (95% CI , 83%–89%) (P<. 05). However, at 9.5 years
post implant, the survival rates were 57% (95% CI , 55%–60%) for
patientswith>80%RVPand59%(95%CI,52%–66%)forpatients
with<20%RVP,whichwerenotsigniﬁcantlydiﬀerent.(RVP=right
ventricular pacing.)
analysis allowed selection of patients with a calculated
frequency of RVP. We wanted the groups to have diﬀerent
treatment eﬀects (either mostly paced or mostly not paced).
The <20% RVP and >80% RVP cutoﬀs, which our group has
previously used, were predetermined to allocate large groups
with either a relatively low level of pacing or a relatively high
level of pacing. Using these two extremes might allow better
detection of a pacing eﬀect. We did not use cutoﬀso f0 %
RVP and 100% RVP, since far too few patients would be
included in the analysis. Nor were cutoﬀss u c ha s<50% RVP
and >50% RVP used, because these might not discriminate
pacing eﬀect: patients in the low-pacing group could have up
to49%pacing,whereasthoseinthehigh-pacinggroupcould
have as little as 51% pacing.
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Figure 5: Survival function for 4 groups. The group variable,
percent pacing, and pacemaker type had a signiﬁcant impact on
survival. Throughout the followup period, patients with dual-
chamber pacemakers were least likely to die, regardless of whether
they had <20% or >80% pacing. Patients with <20% and single-
chamber pacemakers had both the highest percentage of patients
who died (30.8%) and the shortest time to death (25% died by
4.5 years post implant). Patients with >80% and single-chamber
pacemakers also had a high percentage, who died (30.5%), and a
moderate survival time (25% died by 5.2 years).
We found that, despite being signiﬁcantly older at the
time of pacemaker insertion, the group that paced more
frequently did not have a higher incidence of death. When
survival was assessed for the overall group, and at two
additional time points, more frequent right ventricular
pacing did not shorten survival. The higher frequency of
dual-chamber pacing in the >80% RVP group may have
contributed to this diﬀerence. Despite the apparent survival
advantage with more pacing at 4 years, longer followup
suggests that this advantage is lost by 9.5 years. The results of6 Cardiology Research and Practice
Table 7: Cox regression results using age, rate responsiveness, and 4-group pacing variable.
Variable DF Parameter Estimate SE Chi-square P Hazard ratio
Pacing + type 1 .189 0.036 27.90 <.0001 1.208
Simple versus rate responsive 1 .275 .100 7.52 .006 1.316
Age 1 .059 0.004 260.79 <.0001 1.061
Pacing + type is the composite variable of <20% or >80% pacing and single- or dual-chamber pacemaker type.
even longer followup are not known. Furthermore, of those
who died, the <20% RVP group had a signiﬁcantly shorter
survivalfollowingpacemakerimplant.Thesuboptimalphys-
iologic eﬀects of right ventricular pacing therefore do not
appear to lead to a worse mortality outcome. It appears that,
in patients with an appropriate indication for pacemaker
therapy, an increased frequency of right ventricle pacing will
not hasten death. This should be reassuring to both patients
with pacemakers and their physicians.
Thephysiologiceﬀectsofrightventricularpacingarewell
known. These can include atrioventricular dissociation, as
well as valvular regurgitation leading to atrial enlargement
andremodeling,andventriculoatrialconduction,whichmay
predispose patients to atrial ﬁbrillation [4]. Additionally,
ventricular dyssynchrony may alter cardiac hemodynamics
contributing to ventricular remodeling and heart failure
[4, 11]. Whether these physiologic changes ultimately eﬀect
mortality is uncertain. For instance, in the DAVID trial,
dual-chamber pacing leads to worse outcomes, which was
attributed to unnecessary right ventricular pacing [3].
However, several large randomized trials comparing right
ventricular pacing with modalities that more closely mimic
physiologic pacing have demonstrated only minimal diﬀer-
ences in outcomes and no diﬀerence in mortality, but none
of these studies followed as large of a cohort for as long as
in our study [5–7]. For example, the Mode Selection Trial
(MOST) in Sinus Node Dysfunction had 2568 patients with
a mean follow-up of 3 years, and showed that dual-chamber
pacing reduced the risk for atrial ﬁbrillation and signs and
symptoms of heart failure, but did not improve stroke-
free survival [5]. In addition, Connolly et al. compared
patients receiving traditional right ventricular pacing with
“physiologic” pacing (atrial and atrioventricular) and found
that physiologic pacing provided no signiﬁcant beneﬁt over
ventricular pacing for the prevention of stroke or death
due to cardiovascular cause [6]. The Pacemaker Selection
in the Elderly study investigators found that dual-chamber
pacing provided no signiﬁcant diﬀerence in quality of life
over ventricular pacing in those with atrioventricular block
[7]. Furthermore, one study has demonstrated that patients
with atrial ﬁbrillation who undergo AV nodal ablation and
pacemaker implantation with subsequent 100% ventricular
pacing have no diﬀerence in long-term survival compared
with patients who are not paced and only medically rate
controlled [12]. A study of outcomes of atrial pacing
compared to dual-chamber pacing in a large cohort of
Swedish patients paced for sick sinus syndrome showed
no diﬀerence in the standardized mortality ratios for all-
cause mortality [13]. In our study, atrial pacemakers were
excluded, 43% were paced for atrioventricular block, and
83% had dual-chamber pacemakers. Finally, certain patients
with hypertrophic and dilated cardiomyopathies have in fact
seen clinical beneﬁt from right ventricular pacing in small
studies [14, 15].
Despite absence of conclusive evidence demonstrating
a worse mortality outcome, minimizing right ventricular
pacing has become a therapeutic goal in pacemaker patients
[9].Newpacingalgorithmshavebeendevelopedtominimize
right ventricular pacing in dual-chamber pacemakers [16].
In our study, where TTMs were conducted while patients
were stationary, rate responsiveness, which has the potential
to cause patients in the <20% RVP group to be paced even
more often, was associated with better survival. There have
been proposals to use alternative pacing sites such as left
ventricular or biventricular pacing in patients without heart
failure [17, 18]. These approaches are not only more costly,
but also technically challenging and may contribute to a
higher procedural risk or need for repeat procedures.
Inadditiontotheprimaryendpoints,thisstudyvalidated
that when substantial transtelephonic monitoring data is
available it has a high correlation as a surrogate for actual
percentage of ventricular pacing. To our knowledge, this had
not been previously demonstrated. This could have implica-
tions on future study designs and open new opportunities
for research on pacing therapy. Furthermore, it was observed
that, among Eastern Pacemaker Surveillance Center patients
with six or more TTMs, only 23% of patients received
right ventricular pacing between 20% and 80% of the time.
This demonstrates that patients in our study tend to fall
at the extremes of being frequently paced (>80% RVP)
or minimally paced (<20% RVP) while at rest for TTM
recording, which could reﬂect not only pacing indication but
alsopacemakerprogramming.Acomparisonoftheextremes
was made; the eﬀects of right ventricular pacing in the
intermediate groupwith >20% RVP but <80% RVP werenot
assessed.
6. Limitations
Our observations and conclusions should be evaluated
recognizing the inherent limitations of a retrospective study
design. Diﬀerences in pacemaker indication and pacemaker
type between the two groups may have contributed to
better survival despite older age. Although the regional
group analyzed did not show any statistically signiﬁcant
diﬀerence in comorbidities or medications used, it did diﬀer
slightly from the overall cohort. However, these are not large
diﬀerences: the regional group is slightly older, has slightly
more single-chamber pacing in the 20% RVP group, and
slightly less in the 80% RVP group, and has slightly moreCardiology Research and Practice 7
rate-responsive pacing in the >80% RVP group and slightly
less in the <20% RVP group. Regarding the primary survival
analysis, it is possible that unrecognized diﬀerences in care
or patient characteristics account for the lack of a diﬀerence
in observed survival; however this ﬁnding is similar to that
of a Swedish study comparing AAI pacing to DDD pacing
[13]. The actual site of pacing within the right ventricular
c o u l dn o tb ev e r i ﬁ e d .F u r t h e r m o r e ,w h i l ew ew e r ea b l et o
demonstrate the use of TTM data as a reasonable surrogate
for more comprehensive measures of overall percent RV
pacing, it is not a perfect representative. It is notable that the
group with right ventricular pacing greater than 80% of the
time had the ostensible disadvantage of being signiﬁcantly
older at the time of pacemaker insertion. The vast majority
ofpatientsweremale,andtheseresultsmaynotbeapplicable
to female pacemaker patients.
7. Conclusions
In our study more frequent right ventricular pacing was
not followed by an increased or earlier mortality in
this unselected veteran population. Following pacemaker
implantation, multiple variables impacted mortality out-
comes. Kaplan-Meier analysis comparing survival diﬀerence
between all patients with <20% right ventricular pacing
(22.3%) compared to those with >80% right ventricular
pacing (22.4%) showed no diﬀerence (P = .39). When
controlled for age at implant, type of pacemaker, and
rate responsiveness, more frequent right ventricular pac-
ing was associated with overall 36.2% higher likelihood
of survival during ﬁve years of followup (P = .0016).
Most of the diﬀerence in survival occurs during years 3
through 8 post implant. There was little diﬀerence prior to
year 2.
Despite the potential negative physiologic eﬀects of right
ventricular pacing that have been previously demonstrated
in select patient groups, our ﬁndings suggest that right
ventricular pacing per se does not have a deleterious
eﬀect on survival. Review of this large clinical database
suggests that less frequent right ventricular pacing does not
decrease mortality, and that more frequent right ventricular
pacing does not increase mortality in an unselected veteran
population. Thus from a quality assurance perspective, there
does not appear to be a need for reprogramming all patients
to minimize the frequency of right ventricular pacing. Large
prospective or case-controlled studies would be needed to
validate these ﬁndings.
Abbreviations
RVP: Right ventricular pacing
TTM: Transtelephonic monitoring record.
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